by Plus Therapeutics | Jul 30, 2025 | Uncategorized
In a recent interview with Drug Development & Delivery, Marc Hedrick, M.D., President and CEO of Plus Therapeutics, shared insights into the company’s innovative approach to treating central nervous system (CNS) and solid tumor cancers using targeted...
by Plus Therapeutics | Jul 29, 2025 | LM
Leptomeningeal metastases (LM) remain one of the most challenging complications in neuro-oncology. At Plus Therapeutics, we are committed to changing that. Our ongoing ReSPECT-LM dose-optimization trial is currently evaluating the optimal treatment regimen for...
by Plus Therapeutics | Jul 25, 2025 | Uncategorized
We’re excited to announce that Dr. Andrew Brenner, Principal Investigator for multiple ReSPECT clinical trials, will be going LIVE on Instagram next Tuesday, July 29th at 12:30 PM EST. The conversation will take place on the Game On Glio Podcast Instagram...
by Plus Therapeutics | Jul 24, 2025 | Uncategorized
At Plus Therapeutics, our mission is to radically improve outcomes for patients with central nervous system (CNS) cancers through innovative, targeted radiotherapeutics. In a recent Xtalks Clinical Edge™ feature, our President and CEO, Dr. Marc Hedrick, sat down with...
by Plus Therapeutics | Jul 23, 2025 | LM
Plus Therapeutics is pleased to announce the receipt of a $1.6 million advance payment from the Cancer Prevention and Research Institute of Texas (CPRIT), the world’s second-largest public cancer research funding agency. This payment is part of the $17.6 million grant...
Recent Comments